Nodular sclerosis
Template:DiseaseDisorder infobox
|
WikiDoc Resources for Nodular sclerosis |
|
Articles |
|---|
|
Most recent articles on Nodular sclerosis Most cited articles on Nodular sclerosis |
|
Media |
|
Powerpoint slides on Nodular sclerosis |
|
Evidence Based Medicine |
|
Cochrane Collaboration on Nodular sclerosis |
|
Clinical Trials |
|
Ongoing Trials on Nodular sclerosis at Clinical Trials.gov Trial results on Nodular sclerosis Clinical Trials on Nodular sclerosis at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Nodular sclerosis NICE Guidance on Nodular sclerosis
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Nodular sclerosis Discussion groups on Nodular sclerosis Patient Handouts on Nodular sclerosis Directions to Hospitals Treating Nodular sclerosis Risk calculators and risk factors for Nodular sclerosis
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Nodular sclerosis |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Nodular sclerosis (or "NSHL") is a form of Hodgkin's lymphoma which is the most common subtype of HL in developed countries. It usually affects females more than males and has a median age of onset at ~28 years. It is composed of large tumor nodules with lacunar Reed-Sternberg cell (RS cells) surrounded by fibrotic collagen bands.
The British National Lymphoma Investigation further categorized NSHL based upon Reed-Sternberg cells into "nodular sclerosis type I" (NS I) and "nodular sclerosis type II" (NS II), with the first subtype responding better to treatment. [1]
Reference
- ↑ Mauch, Peter (1999). Hodgkin's Disease. Lippincott Williams & Wilkins. p. 107. ISBN 0-7817-1502-4. Unknown parameter
|coauthors=ignored (help)